Literature DB >> 19284481

Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.

A Idbaih1, J Aimard, B Boisselier, Y Marie, S Paris, E Crinière, R Carvalho Silva, F Laigle-Donadey, A Rousseau, K Mokhtari, J Thillet, M Sanson, K Hoang-Xuan, J-Y Delattre.   

Abstract

AIMS: Novel missense mutations of the epidermal growth factor receptor (EGFR) extracellular domain have been recently described in a large series of glioblastomas.
METHODS: The exons 2, 3, 7, 8 and 15 coding for the EGFR extracellular domain were sequenced in a series of 161 consecutive primary glioblastomas and correlated with clinical features of patients in order to determine whether these alterations are linked to specific clinical characteristics of the disease.
RESULTS: Missense mutations were observed in 18 cases (11.2%), and 4 novel mutations were detected, including G178C, A271C, C818A and C1860G. Mutations of the EGFR extracellular domain were not associated with overall survival or with age at onset of the disease. In contrast, the EGFR extracellular domain mutations were significantly associated with patients' gender. Indeed, 15 mutations were observed in men vs. 3 in women (P < 0.05). EGFR extracellular domain mutations were also strongly associated with EGFR amplification (P < 0.0001).
CONCLUSIONS: To our knowledge, EGFR extracellular domain mutations are the first genomic abnormalities associated with gender in primary glioblastomas, although a link between mutations of the EGFR tyrosine kinase domain and gender has been previously made in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284481     DOI: 10.1111/j.1365-2990.2008.00977.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  16 in total

1.  Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Authors:  Zev A Binder; Amy Haseley Thorne; Spyridon Bakas; E Paul Wileyto; Michel Bilello; Hamed Akbari; Saima Rathore; Sung Min Ha; Logan Zhang; Cole J Ferguson; Sonika Dahiya; Wenya Linda Bi; David A Reardon; Ahmed Idbaih; Joerg Felsberg; Bettina Hentschel; Michael Weller; Stephen J Bagley; Jennifer J D Morrissette; MacLean P Nasrallah; Jianhui Ma; Ciro Zanca; Andrew M Scott; Laura Orellana; Christos Davatzikos; Frank B Furnari; Donald M O'Rourke
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

Review 2.  Molecular pathologic diagnosis of epidermal growth factor receptor.

Authors:  Cecile L Maire; Keith L Ligon
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.

Authors:  Yi-Chen Liang; Hong-Ge Wu; Hong-Jian Xue; Qing Liu; Liang-Liang Shi; Tao Liu; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

4.  Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

Authors:  Sharon L Longo; David J Padalino; Sandra McGillis; Kirstin Petersen; Hartmut Schirok; Oliver Politz; Gregory W Canute; Dawn E Post
Journal:  Invest New Drugs       Date:  2011-12-29       Impact factor: 3.850

5.  Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.

Authors:  Anna Luisa Di Stefano; Alberto Picca; Edouard Saragoussi; Franck Bielle; Francois Ducray; Chiara Villa; Marica Eoli; Rosina Paterra; Luisa Bellu; Bertrand Mathon; Laurent Capelle; Véronique Bourg; Arnaud Gloaguen; Cathy Philippe; Vincent Frouin; Yohann Schmitt; Julie Lerond; Julie Leclerc; Anna Lasorella; Antonio Iavarone; Karima Mokhtari; Julien Savatovsky; Agusti Alentorn; Marc Sanson
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

6.  Chromosome 7p11.2 (EGFR) variation influences glioma risk.

Authors:  Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon
Journal:  Hum Mol Genet       Date:  2011-04-29       Impact factor: 6.150

7.  Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Authors:  Antonio Omuro; Timothy A Chan; Lauren E Abrey; Mustafa Khasraw; Anne S Reiner; Thomas J Kaley; Lisa M Deangelis; Andrew B Lassman; Craig P Nolan; Igor T Gavrilovic; Adilia Hormigo; Cynthia Salvant; Adriana Heguy; Andrew Kaufman; Jason T Huse; Katherine S Panageas; Andreas F Hottinger; Ingo Mellinghoff
Journal:  Neuro Oncol       Date:  2012-12-14       Impact factor: 12.300

8.  Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.

Authors:  Andrew S Chi; Daniel P Cahill; David A Reardon; Patrick Y Wen; Tom Mikkelsen; David M Peereboom; Eric T Wong; Elizabeth R Gerstner; Jorg Dietrich; Scott R Plotkin; Andrew D Norden; Eudocia Q Lee; Lakshmi Nayak; Shota Tanaka; Hiroaki Wakimoto; Nina Lelic; Mara V Koerner; Lindsay K Klofas; Mia S Bertalan; Isabel C Arrillaga-Romany; Rebecca A Betensky; William T Curry; Darrel R Borger; Leonora Balaj; Robert R Kitchen; Sudipto K Chakrabortty; Michael D Valentino; Johan Skog; Xandra O Breakefield; A John Iafrate; Tracy T Batchelor
Journal:  JCO Precis Oncol       Date:  2020-06-08

Review 9.  Epidermal growth factor receptor as a therapeutic target in glioblastoma.

Authors:  B Kalman; E Szep; F Garzuly; D E Post
Journal:  Neuromolecular Med       Date:  2013-04-11       Impact factor: 3.843

10.  Reverse engineering of modified genes by Bayesian network analysis defines molecular determinants critical to the development of glioblastoma.

Authors:  Brian W Kunkle; Changwon Yoo; Deodutta Roy
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.